GraniteShares Advisors LLC Has $796,000 Position in DexCom, Inc. (NASDAQ:DXCM)

GraniteShares Advisors LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,416 shares of the medical device company’s stock after selling 1,550 shares during the period. GraniteShares Advisors LLC’s holdings in DexCom were worth $796,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Bartlett & CO. Wealth Management LLC bought a new stake in DexCom in the fourth quarter valued at approximately $27,000. Valley National Advisers Inc. raised its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. Harbour Investments Inc. increased its stake in shares of DexCom by 55.6% during the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock worth $31,000 after purchasing an additional 120 shares during the period. Atlas Capital Advisors LLC bought a new position in shares of DexCom during the second quarter worth approximately $33,000. Finally, MV Capital Management Inc. increased its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold a total of 187,385 shares of company stock valued at $25,256,617 in the last 90 days. 0.41% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Piper Sandler increased their price target on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Price Performance

Shares of DXCM stock traded up $1.96 during trading hours on Tuesday, reaching $136.52. The company’s stock had a trading volume of 3,036,341 shares, compared to its average volume of 2,992,702. The firm’s 50 day simple moving average is $128.82 and its 200-day simple moving average is $115.85. The company has a market capitalization of $52.63 billion, a price-to-earnings ratio of 104.63, a PEG ratio of 2.34 and a beta of 1.20. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the business posted $0.34 EPS. DexCom’s revenue for the quarter was up 26.9% on a year-over-year basis. Sell-side analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.